The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Aylin Dizi Işık und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine, İstanbul, Türkiye. Hauptthemen laut MEDLINE: Fosfomycin, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Fosfomycin is gaining increasing attention for its activity against MDR or XDR pathogens. Currently, IV fosfomycin is a potential option for treating various infections, including urinary tract infections, pneumonia and skin infections when first-line treatments fail.
Objectives
To evaluate the demographic, clinical, microbiological and treatment modality of children received IV fosfomycin to treat infections caused by MDR pathogens since there are few data on the use of fosfomycin in children.
Methods
This study was conducted retrospectively with patients under 18 years of age who were treated with IV fosfomycin for at least 72 h due to infections caused by MDR pathogens between January 2019 and October 2023 at Marmara University Pendik Training and Research Hospital, İstanbul, Türkiye. Data on demographic and clinical features, microbiological findings, treatment modalities and side effects were evaluated.
Results
Twenty-five children, for a total of 32 cases of infection episodes, with a mean age of 11.4 ± 3.92 years who received IV fosfomycin were included. The most frequent comorbidity was chronic pulmonary diseases, and the most common infection needed for IV fosfomycin was MDR Pseudomonas aeruginosa pneumonia. In all cases, fosfomycin was administered in combination with other antibiotics, mainly meropenem–colistin (68.7%) or meropenem (15.6%). Twenty-two (71.9%) cases had favourable clinical responses at the end of therapy.
Conclusions
Our results suggest that IV fosfomycin may be an effective treatment option for MDR pathogens in the paediatric population. Nevertheless, careful stewardship is necessary to maintain efficacy and reduce antimicrobial resistance selection risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine, İstanbul, Türkiye.
ORCID-Profile: Aylin Dizi Işık, Gülşen Akkoç, Zeynep Ergenç, Seyhan Yılmaz, Sevgi Aslan Tuncay, Burcu Parlak, Pınar Canizci Erdemli, Didem Büyüktaş Aytaç, M Çağla Abacı Çapar, Sevliya Öcal Demir, Eda Kepenekli
Zitieren
APA
Dizi Işık, A., Akkoç, G., Ergenç, Z., Yılmaz, S., Aslan Tuncay, S., Parlak, B., Canizci Erdemli, P., Büyüktaş Aytaç, D., Abacı Çapar, M. Ç., Öcal Demir, S., & Kepenekli, E. (2024). The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae204
Vancouver
Dizi Işık A, Akkoç G, Ergenç Z, Yılmaz S, Aslan Tuncay S, Parlak B, et al. The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae204
BibTeX
@article{DiziIk2024,
author = {Dizi Işık, Aylin and Akkoç, Gülşen and Ergenç, Zeynep and Yılmaz, Seyhan and Aslan Tuncay, Sevgi and Parlak, Burcu and Canizci Erdemli, Pınar and Büyüktaş Aytaç, Didem and Abacı Çapar, M Çağla and Öcal Demir, Sevliya and Kepenekli, Eda},
title = {The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae204}
}
EUVIMED